Transcenta Holding Limited (HKG:6628)

Market Cap	639.97M +7.3%
Revenue (ttm)	8.27M -34.0%
Net Income	-226.71M
EPS	-0.55
Shares Out	426.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,500
Open	1.500
Previous Close	1.500
Day's Range	1.410 - 1.500
52-Week Range	1.300 - 5.800
Beta	-0.48
Analysts	Strong Buy
Price Target	15.23 (+950.35%)
Earnings Date	Aug 28, 2026

About Transcenta Holding

Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST808, a humanized antibody neutralizing APRIL targeting B/plasma cell; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a hu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 155
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6628

Financial Performance

In 2025, Transcenta Holding's revenue was 7.44 million, a decrease of -33.98% compared to the previous year's 11.26 million. Losses were -203.73 million, -29.82% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error